Related Experiment Video
Updated: Apr 30, 2026

Quantification of Plasmid-Mediated Antibiotic Resistance in an Experimental Evolution Approach
Published on: December 14, 2019
Investigating specific bacterial resistance to AMPs by using a magainin I-resistant Escherichia coli model
Keyla C de Almeida1, Thais B Lima2, Dielle O Motta2
11] Centro de Análises Proteômicas e Bioquímicas, Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, Brazil [2] Pós-Graduação em Patologia Molecular, Universidade de Brasília, Brasília, Brazil.
Abstract:
Antimicrobial peptides (AMPs) are multifunctional compounds that may show antimicrobial and immunomodulatory activities. With the rapid increase in the incidence of multidrug-resistant bacteria, there is an enormous interest in AMPs as templates for the production of new antibiotics. However, there are concerns that the therapeutic administration of AMPs can select resistant strains. In order to distinguish between resistant and non-resistant strains and verify resistance specificity to AMPs, in this study a magainin I-resistant Escherichia coli model was used. First, the identity of all strains was confirmed by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF)-MS, VITEK 2 and MicroScan, and the susceptible and magainin-resistant strains were successfully differentiated by MALDI-TOF-MS analysis. Furthermore, cross-resistances to a broad spectrum of antibiotics were evaluated, showing that all E. coli strains are susceptible to the drugs tested, suggesting that the resistance seems to be specific to AMPs. Finally, the specific resistance to magainin I compared with other AMPs was checked by microdilution. This experiment showed that the magainin MICs were 62 and 104 μM for susceptible and resistant strains, respectively. The other AMPs MICs were 3.4 μM to proline-arginine-rich 39-amino-acid peptide, 43 μM to porcine myeloid antimicrobial 23-amino-acid peptide-23 and 1.2 μM to cecropin P1 for all strains, demonstrating any additional resistance to peptides here evaluated, confirming that the resistance seems to be essentially specific to magainin I. In summary, the data reported here reinforce the proposal that magainin I seems not to be merely a membrane disruptor, probably showing additional molecular targets in pathogenic bacteria.
Insights
Antimicrobial peptides (AMPs) show promise against multidrug-resistant bacteria. This study used a magainin I-resistant Escherichia coli model to confirm resistance is specific to magainin I, not other antibiotics or AMPs.
Area of Science:
- Microbiology
- Biochemistry
- Drug Discovery
Background:
- Antimicrobial peptides (AMPs) are crucial in combating multidrug-resistant bacteria.
- Concerns exist regarding therapeutic AMP administration potentially selecting for resistant strains.
- Developing methods to differentiate AMP-specific resistance is vital for new antibiotic development.
Purpose of the Study:
- To establish and verify a magainin I-resistant Escherichia coli model.
- To determine if resistance to magainin I confers cross-resistance to conventional antibiotics or other AMPs.
- To investigate potential novel molecular targets of magainin I.
Main Methods:
- Strain identification and differentiation using MALDI-TOF-MS, VITEK 2, and MicroScan.
- Evaluation of cross-resistances to a broad spectrum of antibiotics.
- Microdilution assays to determine specific resistance to magainin I and other AMPs.
Main Results:
- Successfully differentiated magainin I-susceptible and resistant E. coli strains using MALDI-TOF-MS.
- Confirmed that magainin I-resistant E. coli strains remained susceptible to conventional antibiotics.
- Demonstrated specific resistance to magainin I, with no cross-resistance observed to other tested AMPs.
Conclusions:
- Resistance developed against magainin I in E. coli appears to be specific to this peptide.
- Magainin I may possess molecular targets beyond simple membrane disruption in bacteria.
- This finding supports the potential of AMPs as templates for novel antibiotic development without broad cross-resistance concerns.
Related Concept Videos
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Antibiotic Selection

